NCT03710902 Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke
| NCT ID | NCT03710902 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jukka Putaala |
| Condition | Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 405 participants |
| Start Date | 2018-10-17 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 405 participants in total. It began in 2018-10-17 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CARDIOSTROKE is a randomized trial comparing mobile-device assisted control of hypertension together with screening of occult atrial fibrillation to standard care in patients with recent ischemic stroke or transient ischemic attack.
Eligibility Criteria
Inclusion Criteria: * Ischemic stroke or transient ischemic attack (ABCD2 score ≥3) * Age ≥40 years * Pre-existing or newly diagnosed hypertension * Informed consent from the patient or legal representative Exclusion Criteria: * Known high-risk source of cardioembolism * Known indication for anticoagulation * Contraindication for anticoagulation * Pacemaker * Non-compliance to study interventions as judged by the investigator * Serious condition hampering the study conduct
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03710902 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03710902 currently recruiting?
Yes, NCT03710902 is actively recruiting participants. Contact the research team at tuomas.lumikari@helsinki.fi for enrollment information.
Where is the NCT03710902 trial being conducted?
This trial is being conducted at Hämeenlinna, Finland, Helsinki, Finland, Hyvinkää, Finland, Lahti, Finland.
Who is sponsoring the NCT03710902 clinical trial?
NCT03710902 is sponsored by Jukka Putaala. The trial plans to enroll 405 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.